NeoGenomics, Inc. (NEO) Financial Statements (2024 and earlier)

Company Profile

Business Address 9490 NEOGENOMICS WAY
FORT MYERS, FL 33912
State of Incorp. NV
Fiscal Year End December 31
Industry (SIC) 8734 - Testing Laboratories (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments306,239289,074275,609263,180266,126465,953
Cash and cash equivalents306,239289,074275,609263,180266,126283,637
Short-term investments      182,316
Receivables132,640125,425118,842119,711111,994111,276
Inventory, net of allowances, customer advances and progress billings24,05324,94524,43224,27723,79921,863
Inventory24,05324,94524,43224,27723,79921,863
Prepaid expense18,67616,57116,18515,23716,51116,662
Contract with customer, asset, after allowance for credit loss     2,679 
Capitalized contract cost     106 
Other current assets9,3178,4337,6228,0777,5166,506
Other undisclosed current assets96,025120,272142,306174,809174,629 
Total current assets:586,950584,720584,996605,291603,360622,260
Noncurrent Assets
Operating lease, right-of-use asset87,13191,41293,78496,10998,94599,917
Property, plant and equipment94,517100,110102,845102,499106,818111,105
Intangible assets, net (including goodwill)904,676913,459922,243931,026939,614952,453
Goodwill522,766522,766522,766522,766522,766527,115
Intangible assets, net (excluding goodwill)381,910390,693399,477408,260416,848425,338
Other noncurrent assets4,9675,4075,3065,1096,8456,378
Total noncurrent assets:1,091,2911,110,3881,124,1781,134,7431,152,2221,169,853
TOTAL ASSETS:1,678,2411,695,1081,709,1741,740,0341,755,5821,792,113
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities64,41363,59955,60360,65189,69291,409
Employee-related liabilities37,99237,280
Accounts payable16,81917,91322,71220,51013,70816,849
Accrued liabilities47,59445,68632,89140,14137,99237,280
Deferred revenue3,6175,7126,0677,5576,3866,348
Debt 4113870118410
Restructuring reserve 3,7714,1354,0081,519  
Other undisclosed current liabilities21,12121,39120,89020,135(11,193)(15,497)
Total current liabilities:92,92694,84886,60689,93285,00382,670
Noncurrent Liabilities
Long-term debt and lease obligation537,475536,755536,037535,322605,080605,780
Long-term debt, excluding current maturities537,475536,755536,037535,322534,609533,898
Liabilities, other than long-term debt100,412107,313112,069116,75752,51160,144
Deferred income tax liabilities25,37028,81131,71534,75038,34545,979
Other liabilities13,03513,03413,03513,05514,16614,165
Operating lease, liability62,00765,46867,31968,95270,47171,882
Total noncurrent liabilities:637,887644,068648,106652,079657,591665,924
Total liabilities:730,813738,916734,712742,011742,594748,594
Equity
Equity, attributable to parent, including:947,428956,192974,462998,0231,012,9881,043,519
Additional paid in capital1,181,8761,172,8501,167,0511,160,8821,154,3651,146,997
Accumulated other comprehensive loss(1,846)(2,572)(2,834)(3,899)(5,104)(4,056)
Accumulated deficit(232,729)(214,213)(189,882)(159,087)(136,400)(99,548)
Other undisclosed equity, attributable to parent127127127127127126
Total equity:947,428956,192974,462998,0231,012,9881,043,519
TOTAL LIABILITIES AND EQUITY:1,678,2411,695,1081,709,1741,740,0341,755,5821,792,113

Income Statement (P&L) ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Revenues151,954146,917137,220138,705128,782125,072
Cost of revenue
(Cost of Goods and Services Sold)
(89,643)(87,026)(82,406)(81,880)(79,889)(81,126)
Gross profit:62,31159,89154,81456,82548,89343,946
Operating expenses(86,506)(89,785)(89,887)(83,208)(88,403)(83,648)
Operating loss:(24,195)(29,894)(35,073)(26,383)(39,510)(39,702)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(96)730(114)(1)25(405)
Interest and debt expense2,8402,524 860(139)(926)
Loss from continuing operations before equity method investments, income taxes:(21,451)(26,640)(35,187)(25,524)(39,624)(41,033)
Other undisclosed income from continuing operations before income taxes  1,467   
Loss from continuing operations before income taxes:(21,451)(26,640)(33,720)(25,524)(39,624)(41,033)
Income tax benefit2,9352,3092,9252,8372,7725,730
Loss from continuing operations:(18,516)(24,331)(30,795)(22,687)(36,852)(35,303)
Loss before gain (loss) on sale of properties:(36,852)(35,303)
Net loss available to common stockholders, diluted:(18,516)(24,331)(30,795)(22,687)(36,852)(35,303)

Comprehensive Income ($ in thousands)

12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
Net loss:(18,516)(24,331)(30,795)(22,687)(36,852)(35,303)
Comprehensive loss:(18,516)(24,331)(30,795)(22,687)(36,852)(35,303)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent7262621,0651,205(1,048)(1,047)
Comprehensive loss, net of tax, attributable to parent:(17,790)(24,069)(29,730)(21,482)(37,900)(36,350)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: